2023-07-21
Altamira Therapeutics Ltd., a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that it has entered into a collaboration and option agreement with Heqet Therapeutics s.r.l. utilizing the Company’s proprietary OligoPhoreTM delivery platform. Based in Turin, Italy, Heqet is a biotech spin-out from King’s College London. It is...
